Literature DB >> 8740336

Pathophysiology and management of the serotonin syndrome.

T M Brown1, B P Skop, T R Mareth.   

Abstract

OBJECTIVE: To review the symptoms, pathophysiology, and treatment of the serotonin syndrome (SS). DATA SOURCES: A MEDLINE search (1957-1995) of the English-language literature pertaining to the SS was performed. Additional literature was obtained from reference lists of pertinent articles identified through the search. STUDY SELECTION AND DATA EXTRACTION: All articles were considered for possible inclusion in the review. Pertinent information, as judged by the authors, was selected for discussion. DATA SYNTHESIS: The SS, an occasionally fatal disorder, is characterized by symptoms such as mental status changes, seizures, myoclonus, and blood dyscrasias. Both the central and peripheral serotonergic systems and several serotonin receptor types are involved in the symptomatology of the SS. The pathogenesis of SS may be due to endogenous as well as iatrogenic deficits in peripheral serotonin metabolism, a stimulus for release of serotonin, and interactions with other neurotransmitter systems. Lorazepam, serotonin-blockers, and nitroglycerin have been used successfully to treat SS.
CONCLUSIONS: The SS is increasingly recognized and reported in the literature. Clinical and basic science research have increased our understanding of the pathophysiology, conditions, and agents that may predispose to the development of the syndrome. Newer treatment strategies are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740336     DOI: 10.1177/106002809603000517

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  9 in total

Review 1.  Serotonin syndrome and drug combinations: focus on MAOI and RIMA.

Authors:  S E Hilton; H Maradit; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 3.  Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management.

Authors:  Michael J Maher; Simon A Rego; Gregory M Asnis
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Serotonin abnormalities in Dravet syndrome mice before and after the age of seizure onset.

Authors:  Paul G Hatini; Kathryn G Commons
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 5.  Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome.

Authors:  J L Hernández; L Palacios-Araus; S Echevarría; A Herrán; J F Campo; J A Riancho
Journal:  Postgrad Med J       Date:  1997-12       Impact factor: 2.401

Review 6.  Interactions between herbal medicines and prescribed drugs: a systematic review.

Authors:  A A Izzo; E Ernst
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  [Psychopharmacotherapy in emergency medicine].

Authors:  A Wolf; M J Müller; F-G B Pajonk
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-11       Impact factor: 0.840

8.  The serotonin syndrome-the need for physician's awareness.

Authors:  Bhawana Arora; Nirupama Kannikeswaran
Journal:  Int J Emerg Med       Date:  2010-08-20

9.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.